With more than 3.0 million page views and more than 5,000 items, this blog provides news and commentary on public policy, business and economic issues related to the $3 billion California stem cell agency. David Jensen, a retired California newsman, has published this blog since January 2005. His email address is djensen@californiastemcellreport.com.
Thursday, February 28, 2008
AP Story on WARF Patent Matter
Re the WARF patent fight(see item below), here is a link to The Associated Press Story, which has been now carried on the San Jose Mercury News website.
Note that the argument of FTCR and PubPat (that the work University of Wisconsin researcher James Thomson to isolate stem cell lines was obvious in the light of previous scientific research) has been rejected by the USPTO as to the remaining two WARF patents.
The argument of FTCR and PubPat was based on previous work which the USPTO found not to be enabled (ie, didn't teach one of ordinary skill how to carry out the work claimed by WARF). The challenge was in the end, fundamentally frivolous.
Note that the argument of FTCR and PubPat (that the work University of Wisconsin researcher James Thomson to isolate stem cell lines was obvious in the light of previous scientific research) has been rejected by the USPTO as to the remaining two WARF patents.
ReplyDeleteThe argument of FTCR and PubPat was based on previous work which the USPTO found not to be enabled (ie, didn't teach one of ordinary skill how to carry out the work claimed by WARF). The challenge was in the end, fundamentally frivolous.